For research use only. Not for therapeutic Use.
MC-VC-PABC-Aur0101（Cat No.:I018020） is an antibody-drug conjugate (ADC) consisting of Aur0101, an auristatin microtubule inhibitor, conjugated to the ADC linker MC-VC-PABC. This drug-linker conjugate demonstrates potent antitumor activity. Aur0101, as a microtubule inhibitor, disrupts the normal function of cellular microtubules, leading to inhibition of cell division and proliferation. The linker, MC-VC-PABC, allows for the specific delivery of Aur0101 to tumor cells via an antibody. This targeted approach enhances the therapeutic efficacy while minimizing off-target effects, making it a promising strategy in cancer treatment.
| Catalog Number | I018020 |
| CAS Number | 1438849-92-3 |
| Molecular Formula | C₆₈H₁₀₀N₁₂O₁₄S |
| Purity | ≥95% |
| Target | Drug-Linker Conjugates for ADC |
| IUPAC Name | [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[1-[[(2S)-1-[[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]carbamate |
| InChI | InChI=1S/C68H100N12O14S/c1-13-43(6)58(51(92-11)39-55(84)79-36-21-25-50(79)59(93-12)44(7)60(85)74-49(63-70-34-37-95-63)38-45-22-16-14-17-23-45)78(10)64(88)57(42(4)5)76-65(89)68(8,9)77-67(91)94-40-46-27-29-47(30-28-46)72-61(86)48(24-20-33-71-66(69)90)73-62(87)56(41(2)3)75-52(81)26-18-15-19-35-80-53(82)31-32-54(80)83/h14,16-17,22-23,27-32,34,37,41-44,48-51,56-59H,13,15,18-21,24-26,33,35-36,38-40H2,1-12H3,(H,72,86)(H,73,87)(H,74,85)(H,75,81)(H,76,89)(H,77,91)(H3,69,71,90)/t43-,44+,48-,49-,50-,51+,56-,57-,58-,59+/m0/s1 |
| InChIKey | OUOWRIRIGRPGBR-WUDDPNKVSA-N |
| SMILES | CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C3=NC=CS3)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C)(C)NC(=O)OCC4=CC=C(C=C4)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCCCCN5C(=O)C=CC5=O |
| Reference | [1]. Samantha Congreve, et al. Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs. |
